All In Biotech

BLA 206538 · Sanofi US Services

Toujeo Solostar

Insulin Glargine Recombinant · Subcutaneous · Insulin Analog

Last checked: Nov 20, 2026Latest source record: Aug 29, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2015

Feb 25, 2015

Approved uses

n/a

Original approval plus efficacy supplements

Registered trials

9

3 Phase 3, 0 recruiting

FAERS reports

0

0 serious, 0 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

No structured label for this application in openFDA. Older and discontinued products often have none.

Therapeutic areas: Cardiovascular and metabolic

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

FDA's data service is rate-limiting requests. Try again in a minute. The numbers below may be missing or incomplete.

No approvals could be loaded from Drugs@FDA just now.

Clinical trials

Interventional ClinicalTrials.gov studies with "Insulin Glargine Recombinant" as an intervention, any sponsor and status, largest first.

All 9 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
FDA's data service is rate-limiting requests. Try again in a minute. The numbers below may be missing or incomplete.

No FAERS reports name this application.

FAERS reports by year

By the date FDA received the report.

No reports.

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Toujeo Max Solostar (Insulin Glargine,Hum.Rec.Anlog)

2024 spending

$561M

Beneficiaries

134,394

514,108 claims

Per beneficiary

$4,176

$88.80 per unit

View as table
YearSpending
2020$205,860,575
2021$285,075,587
2022$356,666,504
2023$488,777,502
2024$561,185,695

Part D: Toujeo Solostar (Insulin Glargine,Hum.Rec.Anlog)

2024 spending

$550M

Beneficiaries

189,494

762,959 claims

Per beneficiary

$2,902

$88.89 per unit

View as table
YearSpending
2020$569,974,166
2021$540,910,610
2022$505,159,441
2023$541,871,908
2024$549,974,619

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 0 on PubMed

No PubMed clinical studies matched.

Sponsor: Sanofi · Also marketed as Toujeo Max Solostar

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.